Two Sigma Investments, LP Protalix Bio Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.34 - $1.85 $37,118 - $51,245	-27,700 Reduced 58.56%	19,600 $34,000
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.02 $11,659 - $15,806	-7,825 Reduced 14.2%	47,300 $78,000
Q2 2023 Aug 14, 2023	SELL	$2.0 - $3.36 $277,938 - $466,935	-138,969 Reduced 71.6%	55,125 $110,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.16 $252,036 - $397,370	183,968 Added 1816.79%	194,094 $407,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $1.37 $225 - $308	-225 Reduced 2.17%	10,126 $13,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $15,613 - $18,797	-15,159 Reduced 59.42%	10,351 $11,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.56 $26,020 - $39,795	25,510 New	25,510 $28,000

3.58M

61.1K

36.2K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $87.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.